Skip to main content

    Carlsmed (CARL) ratings reaffirmed by 3 firms after its earnings report

    GNG Research Market News

    By GNG Research

    Carlsmed, Inc. (CARL) received rating reaffirmations from three firms on November 11, 2026. Three bullish, zero neutral, zero bearish. No firm changed its rating.

    FirmRatingTier
    BTIGBuybullish
    NeedhamBuybullish
    Truist SecuritiesBuybullish

    Among three firms active over the past 90 days, three hold a bullish rating. Seven analysts set consensus price targets as of November 6, 2026, with a mean of $19.58, a median of $18.36 and a range of $17.17 to $24.15.

    For Q4 FY2026, analysts expect EPS of -$0.39 and revenue of $22.87 million. The next earnings report is scheduled for February 24, 2027.